Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7.

Buffière A, Uzan B, Aucagne R, Hermetet F, Mas M, Nassurdine S, Aznague A, Carmignac V, Tournier B, Bouchot O, Ballerini P, Barata JT, Bastie JN, Delva L, Pflumio F, Quéré R.

Oncogene. 2019 Aug 15. doi: 10.1038/s41388-019-0921-4. [Epub ahead of print]

PMID:
31417180
2.

A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.

Akkapeddi P, Fragoso R, Hixon JA, Ramalho AS, Oliveira ML, Carvalho T, Gloger A, Matasci M, Corzana F, Durum SK, Neri D, Bernardes GJL, Barata JT.

Leukemia. 2019 Mar 8. doi: 10.1038/s41375-019-0434-8. [Epub ahead of print]

PMID:
30850736
3.

IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.

Oliveira ML, Akkapeddi P, Ribeiro D, Melão A, Barata JT.

Adv Biol Regul. 2019 Jan;71:88-96. doi: 10.1016/j.jbior.2018.09.012. Epub 2018 Sep 19. Review.

4.

STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.

Ribeiro D, Melão A, van Boxtel R, Santos CI, Silva A, Silva MC, Cardoso BA, Coffer PJ, Barata JT.

Blood Adv. 2018 Sep 11;2(17):2199-2213. doi: 10.1182/bloodadvances.2018021063.

5.

Multifaceted CK2 in malignant and healthy T cells.

Ribeiro ST, Barata JT, Silva-Santos B.

Oncotarget. 2017 Oct 9;8(53):90622-90623. doi: 10.18632/oncotarget.21700. eCollection 2017 Oct 31. No abstract available.

6.

Therapeutic targeting of CK2 in acute and chronic leukemias.

Buontempo F, McCubrey JA, Orsini E, Ruzzene M, Cappellini A, Lonetti A, Evangelisti C, Chiarini F, Evangelisti C, Barata JT, Martelli AM.

Leukemia. 2018 Jan;32(1):1-10. doi: 10.1038/leu.2017.301. Epub 2017 Sep 27. Review.

7.

Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.

Evangelisti C, Cappellini A, Oliveira M, Fragoso R, Barata JT, Bertaina A, Locatelli F, Simioni C, Neri LM, Chiarini F, Lonetti A, Buontempo F, Orsini E, Pession A, Manzoli L, Martelli AM, Evangelisti C.

J Cell Physiol. 2018 Mar;233(3):1796-1811. doi: 10.1002/jcp.26135. Epub 2017 Sep 7.

PMID:
28777460
8.

From the outside, from within: Biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia.

Oliveira ML, Akkapeddi P, Alcobia I, Almeida AR, Cardoso BA, Fragoso R, Serafim TL, Barata JT.

Cell Signal. 2017 Oct;38:10-25. doi: 10.1016/j.cellsig.2017.06.011. Epub 2017 Jun 21. Review.

9.

IL-7-Induced Proliferation of Human Naive CD4 T-Cells Relies on Continued Thymic Activity.

Silva SL, Albuquerque AS, Matoso P, Charmeteau-de-Muylder B, Cheynier R, Ligeiro D, Abecasis M, Anjos R, Barata JT, Victorino RM, Sousa AE.

Front Immunol. 2017 Jan 19;8:20. doi: 10.3389/fimmu.2017.00020. eCollection 2017.

10.

Casein kinase 2 controls the survival of normal thymic and leukemic γδ T cells via promotion of AKT signaling.

Ribeiro ST, Tesio M, Ribot JC, Macintyre E, Barata JT, Silva-Santos B.

Leukemia. 2017 Jul;31(7):1603-1610. doi: 10.1038/leu.2016.363. Epub 2016 Nov 30.

11.

Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Evangelisti C, Evangelisti C, Buontempo F, Lonetti A, Orsini E, Chiarini F, Barata JT, Pyne S, Pyne NJ, Martelli AM.

Leukemia. 2016 Nov;30(11):2142-2151. doi: 10.1038/leu.2016.208. Epub 2016 Jul 27. Review.

12.
13.

MiR-146b negatively regulates migration and delays progression of T-cell acute lymphoblastic leukemia.

Correia NC, Fragoso R, Carvalho T, Enguita FJ, Barata JT.

Sci Rep. 2016 Aug 23;6:31894. doi: 10.1038/srep31894.

14.

Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage.

Correia NC, Arcangeli ML, Pflumio F, Barata JT.

Leukemia. 2016 Oct;30(10):1968-1978. doi: 10.1038/leu.2016.169. Epub 2016 Jun 13. Review.

PMID:
27443261
15.

Human naïve regulatory T-cells feature high steady-state turnover and are maintained by IL-7.

Silva SL, Albuquerque AS, Serra-Caetano A, Foxall RB, Pires AR, Matoso P, Fernandes SM, Ferreira J, Cheynier R, Victorino RM, Caramalho I, Barata JT, Sousa AE.

Oncotarget. 2016 Mar 15;7(11):12163-75. doi: 10.18632/oncotarget.7512.

16.

microRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia.

Correia NC, Melão A, Póvoa V, Sarmento L, Gómez de Cedrón M, Malumbres M, Enguita FJ, Barata JT.

Oncotarget. 2016 Feb 16;7(7):8268-81. doi: 10.18632/oncotarget.6987.

17.

FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.

Fleskens V, Mokry M, van der Leun AM, Huppelschoten S, Pals CE, Peeters J, Coenen S, Cardoso BA, Barata JT, van Loosdregt J, Coffer PJ.

Oncogene. 2016 Aug 4;35(31):4141-8. doi: 10.1038/onc.2015.481. Epub 2015 Dec 21.

PMID:
26686090
18.

The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.

Cardoso BA, Belo H, Barata JT, Almeida AM.

PLoS One. 2015 Dec 1;10(12):e0143897. doi: 10.1371/journal.pone.0143897. eCollection 2015.

19.

CHK1 and replicative stress in T-cell leukemia: Can an irreverent tumor suppressor end up playing the oncogene?

Sarmento LM, Barata JT.

Adv Biol Regul. 2016 Jan;60:115-121. doi: 10.1016/j.jbior.2015.10.007. Epub 2015 Oct 24. Review.

PMID:
26527132
20.

Checkmate to CHK1 in T-cell ALL?

Sarmento LM, Barata JT.

Oncoscience. 2015 Aug 12;2(9):735-6. eCollection 2015. No abstract available.

21.

Lymphotoxin-β receptor in microenvironmental cells promotes the development of T-cell acute lymphoblastic leukaemia with cortical/mature immunophenotype.

Fernandes MT, Ghezzo MN, Silveira AB, Kalathur RK, Póvoa V, Ribeiro AR, Brandalise SR, Dejardin E, Alves NL, Ghysdael J, Barata JT, Yunes JA, dos Santos NR.

Br J Haematol. 2015 Dec;171(5):736-51. doi: 10.1111/bjh.13760. Epub 2015 Oct 12. Erratum in: Br J Haematol. 2016 Jun;173(5):804.

PMID:
26456771
22.

PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia.

Silveira AB, Laranjeira AB, Rodrigues GO, Leal PC, Cardoso BA, Barata JT, Yunes RA, Zanchin NI, Brandalise SR, Yunes JA.

Oncotarget. 2015 May 30;6(15):13105-18.

23.

Kinases, tails and more: regulation of PTEN function by phosphorylation.

Fragoso R, Barata JT.

Methods. 2015 May;77-78:75-81. doi: 10.1016/j.ymeth.2014.10.015. Epub 2014 Oct 22. Review.

PMID:
25448482
24.

Apoptotic human neutrophil peptide-1 anti-tumor activity revealed by cellular biomechanics.

Gaspar D, Freire JM, Pacheco TR, Barata JT, Castanho MA.

Biochim Biophys Acta. 2015 Feb;1853(2):308-16. doi: 10.1016/j.bbamcr.2014.11.006. Epub 2014 Nov 13.

25.

CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.

Sarmento LM, Póvoa V, Nascimento R, Real G, Antunes I, Martins LR, Moita C, Alves PM, Abecasis M, Moita LF, Parkhouse RM, Meijerink JP, Barata JT.

Oncogene. 2015 Jun 4;34(23):2978-90. doi: 10.1038/onc.2014.248. Epub 2014 Aug 18.

PMID:
25132270
26.

A unified nomenclature and amino acid numbering for human PTEN.

Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, Davé V, den Hertog J, Devreotes P, Eickholt BJ, Eng C, Furnari FB, Georgescu MM, Gericke A, Hopkins B, Jiang X, Lee SR, Lösche M, Malaney P, Matias-Guiu X, Molina M, Pandolfi PP, Parsons R, Pinton P, Rivas C, Rocha RM, Rodríguez MS, Ross AH, Serrano M, Stambolic V, Stiles B, Suzuki A, Tan SS, Tonks NK, Trotman LC, Wolff N, Woscholski R, Wu H, Leslie NR.

Sci Signal. 2014 Jul 1;7(332):pe15. doi: 10.1126/scisignal.2005560.

27.

PTEN and leukemia stem cells.

Fragoso R, Barata JT.

Adv Biol Regul. 2014 Sep;56:22-9. doi: 10.1016/j.jbior.2014.05.005. Epub 2014 Jun 14. Review.

PMID:
24961634
28.

PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events.

Mendes RD, Sarmento LM, Canté-Barrett K, Zuurbier L, Buijs-Gladdines JG, Póvoa V, Smits WK, Abecasis M, Yunes JA, Sonneveld E, Horstmann MA, Pieters R, Barata JT, Meijerink JP.

Blood. 2014 Jul 24;124(4):567-78. doi: 10.1182/blood-2014-03-562751. Epub 2014 Jun 5.

29.

Reduced BAFF-R and increased TACI expression in common variable immunodeficiency.

Barbosa RR, Silva SL, Silva SP, Melo AC, Pereira-Santos MC, Barata JT, Hammarström L, Cascalho M, Sousa AE.

J Clin Immunol. 2014 Jul;34(5):573-83. doi: 10.1007/s10875-014-0047-y. Epub 2014 May 9.

PMID:
24809296
30.

Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.

Gomes AM, Soares MV, Ribeiro P, Caldas J, Póvoa V, Martins LR, Melão A, Serra-Caetano A, de Sousa AB, Lacerda JF, Barata JT.

Haematologica. 2014 Jun;99(6):1062-8. doi: 10.3324/haematol.2013.096438. Epub 2014 Feb 21.

31.

Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.

Martins LR, Perera Y, Lúcio P, Silva MG, Perea SE, Barata JT.

Oncotarget. 2014 Jan 15;5(1):258-63.

32.

IL-7Rα: Mr Hyde's twists and turns.

Barata JT.

Blood. 2013 Dec 19;122(26):4151-2. doi: 10.1182/blood-2013-11-536987.

33.

Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.

Lonetti A, Antunes IL, Chiarini F, Orsini E, Buontempo F, Ricci F, Tazzari PL, Pagliaro P, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Barata JT, Martelli AM.

Leukemia. 2014 Jun;28(6):1196-206. doi: 10.1038/leu.2013.369. Epub 2013 Nov 6.

PMID:
24310736
34.

Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Cappellini A, Barata JT, Martelli AM.

Leukemia. 2014 Mar;28(3):543-53. doi: 10.1038/leu.2013.349. Epub 2013 Nov 20.

PMID:
24253024
35.

The multiple layers of non-genetic regulation of PTEN tumour suppressor activity.

Correia NC, Gírio A, Antunes I, Martins LR, Barata JT.

Eur J Cancer. 2014 Jan;50(1):216-25. doi: 10.1016/j.ejca.2013.08.017. Epub 2013 Sep 19. Review.

PMID:
24054978
36.

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.

Martins LR, Lúcio P, Melão A, Antunes I, Cardoso BA, Stansfield R, Bertilaccio MT, Ghia P, Drygin D, Silva MG, Barata JT.

Leukemia. 2014 Jan;28(1):179-82. doi: 10.1038/leu.2013.232. Epub 2013 Aug 8. No abstract available.

PMID:
23925046
37.

In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas.

Martinho O, Silva-Oliveira R, Miranda-Gonçalves V, Clara C, Almeida JR, Carvalho AL, Barata JT, Reis RM.

Transl Oncol. 2013 Apr;6(2):187-96. Epub 2013 Apr 1.

38.

Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia.

Correia NC, Durinck K, Leite AP, Ongenaert M, Rondou P, Speleman F, Enguita FJ, Barata JT.

Leukemia. 2013 Jul;27(7):1603-6. doi: 10.1038/leu.2013.63. Epub 2013 Mar 1. No abstract available.

PMID:
23448994
39.

IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia.

Ribeiro D, Melão A, Barata JT.

Adv Biol Regul. 2013 May;53(2):211-22. doi: 10.1016/j.jbior.2012.10.005. Epub 2012 Oct 16. Review.

PMID:
23234870
40.

AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications.

Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, Falcieri E, Bortul R, Melchionda F, Iacobucci I, Pagliaro P, Martinelli G, Pession A, Barata JT, McCubrey JA, Martelli AM.

Leukemia. 2012 Jan;26(1):91-100. doi: 10.1038/leu.2011.269. Epub 2011 Oct 4.

PMID:
21968881
41.

Visceral abdominal and subfascial femoral adipose tissue have opposite associations with liver fat in overweight and obese premenopausal caucasian women.

Rocha PM, Barata JT, Minderico CS, Silva AM, Teixeira PJ, Sardinha LB.

J Lipids. 2011;2011:154672. doi: 10.1155/2011/154672. Epub 2011 Sep 22.

42.

Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises.

Sarmento LM, Barata JT.

Expert Rev Anticancer Ther. 2011 Sep;11(9):1403-15. doi: 10.1586/era.11.73. Review.

PMID:
21929314
43.

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.

Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, Tritapoe J, Hixon JA, Silveira AB, Cardoso BA, Sarmento LM, Correia N, Toribio ML, Kobarg J, Horstmann M, Pieters R, Brandalise SR, Ferrando AA, Meijerink JP, Durum SK, Yunes JA, Barata JT.

Nat Genet. 2011 Sep 4;43(10):932-9. doi: 10.1038/ng.924.

PMID:
21892159
44.

On CK2 regulation of chronic lymphocytic leukemia cell viability.

Martins LR, Lúcio P, Silva MC, Gameiro P, Silva MG, Barata JT.

Mol Cell Biochem. 2011 Oct;356(1-2):51-5. doi: 10.1007/s11010-011-0947-6. Epub 2011 Jul 13.

PMID:
21750986
45.

TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.

Cardoso BA, de Almeida SF, Laranjeira AB, Carmo-Fonseca M, Yunes JA, Coffer PJ, Barata JT.

Leukemia. 2011 Oct;25(10):1578-86. doi: 10.1038/leu.2011.140. Epub 2011 Jun 7.

PMID:
21647153
46.

IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias.

Silva A, Laranjeira AB, Martins LR, Cardoso BA, Demengeot J, Yunes JA, Seddon B, Barata JT.

Cancer Res. 2011 Jul 15;71(14):4780-9. doi: 10.1158/0008-5472.CAN-10-3606. Epub 2011 May 18.

47.

Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.

Silva A, Gírio A, Cebola I, Santos CI, Antunes F, Barata JT.

Leukemia. 2011 Jun;25(6):960-7. doi: 10.1038/leu.2011.56. Epub 2011 Apr 1.

PMID:
21455214
48.

Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.

Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM, Cardoso AA.

Exp Hematol. 2011 Apr;39(4):457-472.e3. doi: 10.1016/j.exphem.2011.01.005. Epub 2011 Jan 26.

PMID:
21277936
49.

The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival.

Barata JT.

Adv Enzyme Regul. 2011;51(1):37-49. doi: 10.1016/j.advenzreg.2010.09.012. Epub 2010 Oct 28. Review.

PMID:
21035501
50.

Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.

Martins LR, Lúcio P, Silva MC, Anderes KL, Gameiro P, Silva MG, Barata JT.

Blood. 2010 Oct 14;116(15):2724-31. doi: 10.1182/blood-2010-04-277947. Epub 2010 Jul 21.

Supplemental Content

Loading ...
Support Center